[12] Patent
[11] Patent No.:GC0007792  
[45] Date of Publishing the Grant of the Patent: 31/May /2018                49/2018  
Number of the Decision to Grant the Patent:2018/127575
Date of the Decision to Grant the Patent:17/May/2018

[21] Application No.:GC 2011-19215

[22] Filing Date:5/9/2011

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
14/3/2011
61/452,578

[72] Inventors:1- Michael David BARTBERGER،2- Ana Gonzalez Buenrostro،3- Hilary Plake BECK،4- Chen, Xiaoqi،5- Richard Victor CONNORS،6- Deignan, Jeffrey،7- Duquette, Jason،8- Eksterowicz, John،9- Fisher, Benjamin،10- Brian Matthew FOX،11- Fu, Jiasheng،12- Fu, Zice،13- Gonzalez Lopez de Turiso, Felix،14- Michael William GRIBBLE,JR.،15- Darin James GUSTIN،16- Julie Anne HEATH،17- Huang, Xin،18- Jiao, Xianyun،19- MICHAEL G. JOHNSON،20- Kayser, Frank،21- David John KOPECKY،22- Sujen LAI،23- Li, Yihong،24- Li, Zhihong،25- Liu, Jiwen،26- Jonathan Dante LOW،27- Brian Stuart LUCAS،28- Ma, Zhihua،29- Lawrence MCGEE،30- McIntosh, Joel،31- McMinn, Dustin،32- Julio Cesar MEDINA،33- Jeffrey Thomas MIHALIC،34- Steven Howard OLSON،35- Rew, Yosup،36- Philip Marley ROVETO،37- Sun, Daqing،38- Wang, Xiaodong،39- Wang, Yingcai،40- Xuelei YAN،41- Yu, Ming،42- Zhu, Jiang

[73] Owner: AMGEN INC, One amgen Center Drive, CA 91320-1799, Thousand Oask, USA

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: A61K 31/4412; A61P 35/00; C07D 211/40, 279/02, 401/04, 401/06, 401/12, 407/04, 407/06, 409/04, 413/06, 417/06, 471/20, 498/08, 498/20 (2006.01)

[56] Cited Documents:

-WO 2010/028862 A1 (PRIAXON AG [DE]; BURDACK CHRISTOPH [DE]; KALI NSKI CED R IC [DE]; ROSS GU) 18 March 2010  
Examiner: PH. Rifca AlSadoon

[54] PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER
[57] Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
No. of claims: 4


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.